AlphAIAlphAI — Financial news for AI agents
investing.comOCT 292 min read$ALNY

Alnylam earnings beat by $14.52, revenue topped estimates

Alnylam (ALNY) reported Q3 EPS of $16.26, exceeding estimates by $14.52, with revenue at $1.46B, topping expectations. FY 2026 revenue guidance is $4.70B-$5.10B, below consensus. Stock is up 13.08% in 3 months, down 48.31% in 12 months. InvestingPro rates its financial health as 'great performance'.

Original reporting
investing.com
Published Oct 29, 2026, 12:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 12:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ALNY
Bearish
high confidence
Mentioned
$ALNY
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ALNYBearishHigh
01

Why it matters

The earnings surprise may provide short-term upside, yet the guidance shortfall is likely to drive the stock lower.

02

Market read

Earnings release is a primary catalyst for ALNY, influencing biotech sector sentiment.

03

What to watch

Potential pipeline milestones not discussed may offset guidance concerns.

Relevance 8/10Novelty 8/10Timing: post-earnings today

Background

Alnylam reported Q3 results with a large earnings beat but issued FY2026 revenue guidance below analyst expectations.

Company-level read

Ticker impact

$ALNYBearishHigh confidence
Context

Q3 EPS $16.26 beats estimate by $14.52 and revenue $1.46B tops $1.43B consensus.

Expected impact

likely downside pressure as market prices in weaker guidance

Evidence & confidence

Guidance miss outweighs beat, prompting investors to reassess growth outlook.

Market effects

Sector

Biotech sector may see modest pullback as guidance miss signals slower revenue growth.

Regional

US biotech stocks could face short-term weakness.

Global

Limited to investors tracking biotech earnings cycles.

Counterpoint

What could challenge this read

Beat magnitude could support a short-term rally before guidance impact fully digests.

Key entities

  • company
    Alnylam

    Biotech firm developing RNAi therapeutics.

Read at source← All news

StoryAlnylam Q3 2026 earnings beat, expands nucresiran trial and reaffirms FY‑26 outlook

Also covered by

4 outlets

Related articles

OCT 29
$ALNYMed

Alnylam Pharmaceuticals Q3 Earnings Call Highlights

Alnylam Pharmaceuticals reported that AMVUTTRA has access for 99% of covered lives, with 90% of patients within 10 miles of treatment. The company is monitoring a proposed CMS rule that could reduce Medicare reimbursement for 340B drugs, which represents a meaningful portion of its business. UnitedHealth implemented a restrictive policy for AMVUTTRA, potentially delaying access for new patients.

finance.yahoo.com2 min
OCT 29
$ALNYHighAI 8/10

Alnylam (ALNY) Q3 2026 Earnings Call Transcript

Alnylam (ALNY) reported Q3 2026 revenue of $1.46B, up 17% YoY, driven by TTR franchise growth. AMVUTTRA sales rose 65% YoY to $1.13B. Guidance for TTR product sales was lowered to the range of $4.2B-$4.5B. Management cited Medicare Advantage policy changes and 340B reimbursement adjustments as risks. TRITON-CM study enrollment target was expanded to 2,250 patients.

fool.com3 min
OCT 29
$ALNYMed

Alnylam Sinks 19% as It Expands Nucresiran Heart Trial Again, Citing “A High Level of Conviction”

Alnylam Pharmaceuticals (ALNY) shares fell 19% after expanding its nucresiran heart trial to 2,250 patients, citing confidence in positive results. Despite 52% product revenue growth, concerns arise about nucresiran's benefit. Analysts expect revenue growth through 2028, driven by AMVUTTRA. Competitors like Pfizer (PFE) and BridgeBio (BBIO) may gain if nucresiran's data is weak.

finance.yahoo.com2 min
OCT 29
$ALNYHighAI 8/10

Alnylam Reports 17% Q3 Revenue Growth, Expands Nucresiran Trial And Advances RNAi Pipeline

Alnylam Pharmaceuticals (ALNY) reported Q3 2026 revenue growth of 16.7% to $1.458 billion, driven by a 52% increase in global net product revenue, primarily from its TTR franchise. Net income rose to $2.167 billion. The company expanded its Phase 3 study for nucresiran and presented promising early data for brezosiran in Huntington's disease. Alnylam also advanced its pipeline with mivelsiran and ALN-5288 for neurological diseases.

rttnews.com3 min